FINWIRES · TerminalLIVE
FINWIRES

Stifel Canada在DPM Metals公布第一季度业绩后维持“买入”评级;目标价维持在61.00加元。

By

-- Stifel Canada周三重申对DPM Metals(DPM.TO)股票的“买入”评级,目标价为61.00加元,此前该公司公布了第一季度业绩。 在提前公布8.4万盎司金当量产量后,DPM公布的现金流(扣除营运资本后的每股现金流为0.94美元,高于市场预期的0.91美元)和自由现金流(超出预期13%)略微超出预期,这主要得益于Vares矿区维持成本为892美元/盎司,比市场预期的1048美元/盎司低15%。公司维持此前的产量指引,预计2026年第一季度产量将达到30.5万至36.5万盎司金当量目标中值的25%。本季度,市场关注的焦点在于Vares矿区能否按计划逐步提高产量,以达到DPM将于2025年发布的最新可行性研究报告的要求。为此,我们看到DPM运营价值正按计划逐步实现,贵金属的品位和回收率均高于2025年的研究预期,这支持了DPM的策略,并降低了运营风险,为2027年启动(取决于许可证审批情况)的Coka Rakita项目建设奠定了基础。DPM目前的交易价格为……分析师科尔·麦吉尔写道:“该公司市净率为0.68倍,高于同业的0.52倍,并拥有令人瞩目的内生增长前景,预计到2030年,其黄金当量产量将达到每年50万盎司。” (报道北美、亚洲和欧洲主要银行及研究机构的股票、大宗商品和经济研究。研究机构可通过以下链接联系我们:https://www..com/contact-us

Price: $47.25, Change: $+3.39, Percent Change: +7.73%

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL